Federal Register / Vol. 60, No. 89 / Tuesday, May 9, 1995 / Notices 24649

federally listed species present was not

economically feasible.

John E. Cross,

Acting Regional Director, Region 2,

Albuquerque, New Mexico.

[FR Doc. 95–11352 Filed 5–8–95; 8:45 am]

BILLING CODE 4510–55–M

INTERSTATE COMMERCE

COMMISSION

[Docket No. AB–167 (Sub–No. 1145X)]

Consolidated Rail Corporation—

Abandonment Exemption—

Philadelphia, PA

AGENCY: Interstate Commerce

Commission.

ACTION: Notice of exemption.

SUMMARY: Under 49 U.S.C. 10505, the

Commission exempts from the prior

approval requirements of 49 U.S.C.

10903–10904 the abandonment by

Consolidated Rail Corporation (Conrail)

of the 1.64-mile ‘‘City Branch’’, between

milepost 0.66 at the east side of Broad

Street, and milepost 2.3 at the east side

of 30th Street, in Philadelphia,

Philadelphia County, PA. The

exemption is subject to trail use, public

use, historic preservation, and labor

protective conditions.

DATES: The exemption will be effective

May 26, 1995, unless stayed or a

statement of intent to file an offer of

financial assistance (OFA) is filed.

Statements of intent to file an OFA

under 49 CFR 1152.27(c)(2), requests for

a notice of interim trail use/rail banking

under 49 CFR 1152.29, petitions to stay,

requests for a public use condition

under 49 CFR 1152.28, and petitions to

reopen must be filed by May 22, 1995.

ADDRESSES: An original and 10 copies of

all pleadings, referring to Docket No.

AB–167 (Sub-No. 1145X), must be filed

with the Office of the Secretary, Case

Control Branch, Interstate Commerce

Commission, 1201 Constitution Avenue,

NW., Washington, DC 20423. In

addition, a copy of all pleadings must be

served on John J. Paylor, Consolidated

Rail Corporation, 2001 Market Street,

16A, Philadelphia, PA 19101.

FOR FURTHER INFORMATION CONTACT:

Joseph H. Dettmar, (202) 927–5660.

[TDD for the hearing impaired: (202)

927–5721.]

SUPPLEMENTARY INFORMATION:

Additional information is contained in

the Commission’s decision. To purchase

a copy of the decision, write to, call or

pick up in person from Dynamic

Concepts, Inc., Interstate Commerce

Commission Building, 1201

Constitution Avenue, N.W., Room 2229,

Washington, DC 20423. Telephone:

(202) 289–4357/4359. [Assistance for

the hearing-impaired is available

through TDD services at (202) 927–

5721.]

Decided: May 1, 1995.

By the Commission, Chairman Morgan,

Vice Chairman Owen, and Commissioners

Simmons and McDonald.

Vernon A. Williams,

Secretary.

[FR Doc. 95–11363 Filed 5–8–95; 8:45 am]

BILLING CODE 7035–01–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA No. 132P]

Controlled Substances: Proposed 1995

Aggregate Production Quotas

AGENCY: Drug Enforcement

Administration.

ACTION: Notice of proposed revised

aggregate production quotas for 1995.

SUMMARY: This notice proposes revised

1995 aggregate production quotas for

controlled substances in Schedules I

and II, as required under the Controlled

Substances Act of 1970.

DATES: Comments or objections should

be received on or before June 8, 1995.

ADDRESSES: Send comments or

objections to the Administrator, Drug

Enforcement Administration,

Washington, DC 20537, Attn: DEA

Federal Register Representative/CCR.

FOR FURTHER INFORMATION CONTACT:

Howard McClain, Jr., Chief, Drug &

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, DC 20537, Telephone:

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section

306 of the Controlled Substances Act

(CSA) (21 U.S.C. 826) requires that the

Attorney General establish aggregate

production quotas for all controlled

substances listed in Schedules I and II.

This responsibility has been delegated

to the Administrator of the DEA

pursuant to § 0.100 of Title 28 of the

Code of Federal Regulations.

The Administrator, in turn, has

redelegated this function to the Deputy

Administrator of the DEA by § 0.104 of

Title 28 of the Code of Federal

Regulations.

On October 20, 1994, a notice of the

1995 established aggregate production

quotas was published in the Federal

Register (59 FR 52991). The notice

stipulated that the Deputy

Administrator of the DEA would adjust

the quotas in early 1995 as provided for

in Title 21, Code of Federal Regulations,

§ 1303.23(c). These aggregate production

quotas represent those amounts of

controlled substances that may be

produced in the United States in 1995

and do not include amounts which may

be imported for use in industrial

processes.

The proposed revisions are based on

a review of 1994 year-end inventories,

1994 disposition data submitted by

quota applicants, estimates of the

medical needs of the United States

submitted to the DEA by the Food and

Drug Administration and other

information available to the DEA.

Therefore, under the authority vested

in the Attorney General by section 306

of the CSA of 1970 (21 U.S.C. 826),

delegated to the Administrator by

§ 0.100 of Title 28 of the Code of Federal

Regulations, and redelegated to the

Deputy Administrator by § 0.104 of Title

28 of the Code of Federal Regulations,

the Deputy Administrator of the DEA

hereby proposes the following changes

in the 1995 aggregate production quotas

for the listed controlled substances,

expressed in grams of anhydrous acid or

base.

Basic class

Previously established 1995

aggregate production quotas

Proposed revised 1995 aggregate production quotas

Schedule I:

Acetylmethadol ................................................................................................................................................. 2 7

Alphacetymethadol ........................................................................................................................................... 0 5

Aminorex ........................................................................................................................................................... 2 7

Bufotenine ......................................................................................................................................................... 10 10

Cathinone .......................................................................................................................................................... 4 9

Difenoxin ........................................................................................................................................................... 14,000 14,000